Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AGS 16C3F

Next Previous
Drug Profile

AGS 16C3F

Alternative Names: AGS-16C3F; AGS-16M8F; Anti-ENPP3-MMAF

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agensys
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Renal cell carcinoma

Most Recent Events

  • 26 Apr 2017 Agensys and Astellas Pharma completes a phase I trial for Renal cell carcinoma (Metastatic disease, Second-line therapy or greater) in USA (NCT01672775)
  • 31 Jan 2017 Phase-II clinical trials in Renal cell carcinoma in Europe (IV) (Astellas Pharma pipeline, January 2017)
  • 01 Feb 2016 Phase-II clinical trials in Renal cell carcinoma (Second-line therapy or greater, Metastatic disease) in USA, Canada (IV) (NCT02639182)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top